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GENERAL INTRODUCTION 
Thesis Organization 
This thesis starts with a general introduction including hypothesis, objectives, specific 
aims, limitations, and significance of the proposed study followed by a review of literature 
and a manuscript to be submitted to the Journal of Nutrition.  
Hypothesis 
Daily consumption of two servings of soy foods for 10 wk does not significantly 
affect iron and zinc status or thyroid status but may have beneficial effects on bone turnover 
in women of childbearing age. 
Objectives 
1. The primary objective is to determine the effect of consuming two servings of soy 
foods per day for 10 wk, compared to animal food, on iron and zinc status in women 
of childbearing age. 
2. The secondary objective is to investigate whether the consumption of two servings of 
soy foods per day for 10 wk, compared to animal food consumption, affects 
biochemical markers of bone and thyroid hormones in women of childbearing age.  
Specific Aims 
1. To determine the effect of soy food consumption on iron status as measured by serum 
iron, transferrin saturation, total iron binding capacity, transferrin receptor, ferritin, 
transferrin receptor-ferritin index (calculated based on ferritin and transferrin 
receptor), hemoglobin, and hematocrit. 
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2. To determine the effect of soy food consumption on zinc status as measured by serum 
and urinary zinc, as well as serum alkaline phosphatase concentrations. 
3. To test the effect of soy food consumption on biochemical markers of bone as 
measured by serum bone-specific alkaline phosphatase (bone formation marker) and 
CTx (bone resorption marker). 
4. To determine the effect of soy food consumption on thyroid status as measured by 
thyroid stimulating hormone and free thyroxine.  
Limitations 
There are several limitations of this study. A 10-wk intervention may be not long 
enough to result in significant changes in the outcomes we measured. Nutrient intakes of 
subjects were not strictly controlled during the intervention, since they maintained freely 
chosen diets except for the meals we provided, the prohibition of additional soy food intake, 
and meat intake restriction (<3 oz/d). In addition, subjects were required to consume only 3 
out of 14 provided meals on site each week; thus, compliance for most meals except for the 
consumption of test meals might have affected our results. We could not assess dietary zinc, 
iodine and phytate intake due to lack of information in the dietary analysis software. Thus, 
the change in dietary intake of zinc, iodine and phytate may have influenced our results.  
Significance 
Single meal studies have shown apparent inhibition of soy food consumption on iron 
and zinc absorption. However, data are limited and conflicting from long term studies. Thus, 
it is important to investigate the effect of incorporating commonly consumed soy foods to 
daily diets on mineral status in women of childbearing age who are at risk of mineral 
3 
 
deficiencies. The possible benefits of soy consumption on biochemical markers of bone as 
well as the potential risk of an anti-thyroid effect were also determined.  
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REVIEW OF LITERATURE 
I. IRON METABOLISM 
Importance of Iron 
Iron is an essential nutrient for human health because it plays an important role in 
many biochemical processes to maintain normal cellular functions, which include electron 
transport (cytochrome, iron-sulfur proteins), handling of molecular oxygen (peroxidase, 
catalase), oxygen transport and storage (hemoglobin and myoglobin), porphyrin metabolism, 
collagen synthesis, lymphocyte and granulocyte function, and neurotransmitter anabolism 
and catabolism (Pollitt & Leibel, 1976; Cammack et al., 1990). 
Both iron deficiency and excess have harmful effects on human health. Severe iron 
deficiency causes anemia and results in developmental delay and cognitive impairment in 
children and infants (McCann & Ames, 2007), fatigue and reduced work capacity in adults 
(Haas & Brownlie, 2001), as well as adverse pregnancy outcomes in women (Ronnenberg et 
al., 2004; Lee et al., 2006). Iron supplementation increased night sleep duration and 
decreased night waking in infants and improved cognition in older children (Gera & 
Sachdev, 2009; Kordas et al., 2009) in fact suggests the importance of iron. In case of genetic 
or secondary iron overload, excessive iron is deposited in parenchymal cells of the liver and 
other organs, damaging organ structure and function (Crichton, 2006). For example, in 
hereditary hemochromatosis, the absorption of dietary iron increases abnormally so that iron 
accumulates in organs such as the liver and pancreas, leading to cirrhosis and diabetes (Hash, 
2001; Kohgo et al., 2008). Moreover, iron was found to increase with age and iron excess has 
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been associated with neoplasia (Weinberg, 1994), atherosclerosis (Sullivan, 2008), and 
neurodegenerative diseases (Sipe et al., 2002).  
Body Iron Distribution 
Total iron in the body is approximately 3 to 4 g depending on age, weight, and gender 
(Wood & Ronnenberg, 2005). It may be divided into three major compartments: functional 
iron, storage iron, or transport iron, as described in Table 1 (Crichton, 2006). Functional iron 
consists of iron bound to hemoglobin in the erythrocytes, myoglobin in muscles, and iron-
containing enzymes in all cells of the body, respectively accounting for about 65%, 10% and 
2% of body iron. Storage iron associated with ferritin and hemosiderin is primarily located in 
the liver, comprising approximately 20% of body iron. Transport iron is bound to transferrin 
in plasma. Although it accounts for only about 0.8% of body iron, as much as 30 mg of iron 
cycles through this compartment daily to meet the erythropoietic needs. Additionally, some 
intracellular iron (2.2%) termed as ‘labile iron’ is readily utilized within the cells, acting as 
both functional and storage iron in the body (Fairbanks, 1999; Wood & Ronnenberg, 2005).  
Table 1. Typical Iron Distribution in Adults 
 Men Women 
 mg Iron/kg Body Weight
Functional iron   
     Hemoglobin  32 28 
     Myoglobin  5 4 
     Iron-containing enzymes 1-2 1~2 
Storage iron   
     Ferritin (and hemosiderin) ~11 ~6 
Transport iron    
     Transferrin 0.04 0.04 
Source: (Crichton, 2006) 
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Iron Absorption, Regulation, and Distribution 
There are two types of dietary iron: heme iron mainly existing in hemoglobin and 
myoglobin from animal sources, but also present in plants in a low concentration (Kundu et 
al., 2003), and non-heme iron derived from both plant and animal foods (about 35-40% of 
iron in meats, fish, and poultry exists as non-heme iron) (Monsen, 1988). Heme and non-
heme iron are absorbed by different pathways. After digestion, heme iron is released from 
globin (Grasbeck et al., 1982) and enters enterocytes as an intact metaloporphyrin (Conrad et 
al., 1967) possibly through a receptor-mediated endocytosis or heme transporter (West & 
Oates, 2008a).  Iron (ferrous) is then released from the porphyrin ring by heme-oxygenase, 
entering the labile iron pool (Carpenter & Mahoney, 1992; West & Oates, 2008b). In 
contrast, non-heme iron is liberated from foods after gastric digestion and present as ferric 
and ferrous iron in the small intestine (alkaline conditions). In the small intestine, ferric iron 
readily precipitates, but ferrous iron remains relatively soluble and can be absorbed into 
enterocytes by a divalent metal transporter-1 (DMT1). Ferric iron may also be absorbed after 
reduction to ferrous iron by duodenal cytochrome-b (Dcytb). Ferrous iron from both heme 
and non-heme iron enters the labile iron pool, which can be either stored as ferritin in the 
enterocytes or exported across the basolateral membrane of enterocytes into circulation by 
ferroportin-1 (FPN-1) (Crichton, 2006; Dunn et al., 2007). Iron is also released from 
catabolized senescent erythrocytes (consists of 80% of the circulating iron) and the liver 
(Knutson & Wessling-Resnick, 2003). In circulation, iron is transported by transferrin and 
before incorporation into apotransferrin, ferrous iron is oxidized into ferric iron by 
hephaestin (a membrane-bound protein) or serum ceruloplasmin (Crichton, 2006; Dunn et 
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al., 2007). Iron (iron-bound transferrin) is then taken up by cells through transferrin receptor-
mediated endocytosis (Aisen, 2004) for use or storage.  
In iron deficient conditions, iron regulatory protein binds to iron response element 
and regulates transferrin receptor (TfR) and ferritin expression by stabilizing TfR against 
degradation or inhibiting ferritin translation so as to increase iron uptake and decrease 
storage; while in iron sufficient conditions, iron regulatory protein reacts inversely (Dunn et 
al., 2007). Hepcidin produced by the liver is another important modulator for iron absorption 
and mobilization. In iron replete conditions, hepcidin expression increases; it directly binds 
to FPN-1 and causes FPN-1 to be internalized and degraded so as to inhibit intestinal iron 
transport and the release of iron from the reticuloendothelial system that recycles iron from 
senescent erythrocytes (Donovan et al., 2000; Fleming & Bacon, 2005).  
Heme iron has higher bioavailability than non-heme iron because the heme pyrrole 
structure protects against the interference from iron chelators such as polyphenols and 
phytate (Andrews, 2005). Heme iron absorption is enhanced by peptides and amino acids 
produced from meat hydrolysis (Carpenter & Mahoney, 1992) and inhibited by dietary 
calcium intake (Gleerup et al., 1995). Non-heme iron absorption is affected by many dietary 
factors such as polyphenols, phytate and calcium acting as inhibitors and ascorbic acid and 
‘meat factors’ as enhancers (Davidsson et al., 1998; Baech et al., 2003; Hurrell et al., 2006). 
Iron absorption is also influenced by some specific conditions such as iron deficiency and the 
late stage of pregnancy (Wood & Ronnenberg, 2005). For example, a single meal study with 
a group of women showed that heme iron was significantly better absorbed than non-heme 
iron (16.1% vs 4.6%); the non-heme iron absorption increased in iron deficient women 
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compared to normal women (9.5% vs 4.6%) (Ekman & Reizenstein, 1993). It is estimated 
that heme iron contributes to approximately two-thirds of the individual’s total iron stores 
despite constituting only one-third of dietary iron in western countries (Carpenter & 
Mahoney, 1992). 
Generally, about 1-2 mg iron is absorbed from the gastrointestinal (GI) tract when 
dietary iron intake is 10 to 15 mg. Iron absorbed from GI tract and released from catabolized 
senescent erythrocytes and iron stores is delivered by transferrin to bone marrow for 
hemoglobin synthesis (70-90%) and other tissues for utilization (synthesis of myoglobin and 
iron-containing compounds) or to the liver for storage (Figure 1) (Conrad & Umbreit, 2000).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic for Iron Kinetics 
Source: (Conrad & Umbreit, 2000) 
Iron Requirements 
In healthy individuals, daily iron losses are estimated to be 1 mg in men and 1.5 mg 
in women, one half of which are lost through the intestine, including occult blood losses 
Erythrocyte iron 
2500 mg 
Plasma iron 
4 mg 
Body stores 
ferritin, hemosiderin 
1000 mg 
Tissues 
myoglobin, enzymes 
300 mg
absorption 
1~2 mg 
loss 
1~2 mg 
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(0.35 mg/d), sloughed enterocytes as ferritin iron (0.10 mg/d), and iron in biliary secretions 
(0.2 mg/d). Other iron losses are via urine (0.08 mg/d), the shedding of skin cells (0.2 mg/d), 
and sweat in smaller amounts (Cook et al., 1992; Wood & Ronnenberg, 2005). Additionally, 
a significant amount of iron is lost during menstruation in women of childbearing age, 
placing them at greater risk of iron deficiency (Wood & Ronnenberg, 2005).  
Apart from obligatory iron losses, infants and children need additional iron for 
growth and development. Based on 10% absorption efficiency of iron, the current 
recommended iron intake is 8 mg/d for adult males and postmenopausal women, 18 mg/d for 
premenopausal women (Food and Nutrition Board & Institute of Medicine, 2000). Details on 
the dietary reference intake of iron are shown in Table 2 (Food and Nutrition Board & 
Institute of Medicine, 2000).  
Table 2. Dietary Reference Intakes (DRI) Across the Life Span 
 DRI (mg/d iron) 
Infants  
    0-0.5 yr 0.27 (AI) 
    0.5-1 yr 11 
Children  
    1-3 yr 7 
    4-8 yr 10 
    9-13 yr 8 
Males  
    14-18 yr 11 
    >19 yr 8 
Females  
    14-18 yr 15 
       Pregnant 27 
       Lactating  10 
    19-50 yr 18 
       Pregnant 27 
       Lactating  9 
    >50 yr 8 
Source:  (Food and Nutrition Board & Institute of Medicine, 2000) 
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Dietary iron intake 
Diet generally contains 5-7 mg iron per 1000 kcal. When consuming a western-style 
diet to meet energy requirements, adults are estimated to ingest 10-20 mg iron per day. 
However, in some developing countries where the diet is mainly based on plants, the dietary 
iron intake may be adequate but the absorption might be low due to the high content of 
inhibitors, such as phytate and polyphenols present in foods, and low intake of animal tissues 
and ascorbic acid (Wood & Ronnenberg, 2005).  
Meat, fish and poultry are rich sources of iron containing both heme and non-heme 
iron. Cereals, breads, and grain products that are enriched with iron are very good sources of 
non-heme iron. Legumes and green leafy vegetables are also good source of non-heme iron. 
The contribution of these foods to the US dietary iron intake is shown in Figure 2 (Haymes, 
2006).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Constitution of US Dietary Iron Intake 
Source: (Haymes, 2006) 
Assessment of Iron Status 
Stages in developing iron deficiency are shown in Figure 3 (Herbert, 1987). 
Individuals are in normal iron status when their functional needs for iron are satisfied. 
 
33%
33%
15%
22%
Meat, fish, poultry 
Cereals, grain products
Vegetables, fruits
Others: eggs, legumes, and 
dairy products etc
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Besides that, they have sufficient iron stores to meet the increased iron requirements in 
specific conditions, such as pregnancy (Bothwell, 1996). Iron stores vary among individuals 
but the average iron stores for iron replete subjects with western diets are 1000 mg in males 
and 300 mg in females (Bothwell et al., 1979). Iron depletion is the state when storage iron is 
used up but the functional iron has not been impaired; thus, no adverse consequences are 
expected at this stage. Further reduction in body iron leads to iron deficient erythropoiesis, 
since iron is insufficient for the needs of the erythroid marrow, which is associated with an 
increase in erythrocyte zinc protoporphyrin and TfR. Hemoglobin may still be in the normal 
range but anemia gradually develops with time. In severe iron deficiency, individuals 
develop anemia. Since the production of hemoglobin is impaired, individuals manifest with 
microcytic and hypochromic anemia, showing clinical signs of deficiency (Bothwell, 1996).  
Biochemical indicators used for the assessment of iron status are described in the 
following text. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Sequential Stages of Iron Status 
Source: (Herbert, 1987) 
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Serum Ferritin 
Serum ferritin is widely used as a marker of storage iron, and it is particularly useful 
in the identification of mild iron deficiency. Although iron stores can also be assessed by 
bone-marrow and liver biopsies or quantitative phlebotomy, these methods are invasive and 
thus not performed routinely (Baynes, 1996). Ferritin is primarily stored in liver but a small 
amount of ferritin also circulates in blood, the concentration of which reflects body iron 
stores. In healthy individuals and those at the early stage of iron deficiency, serum ferritin 
concentration is proportional to iron stores. For example, 1 µg/L represents 8-10 mg of 
storage iron in healthy adults. When serum ferritin level drops below 12 µg/L, it indicates the 
depletion of iron stores (Bothwell et al., 1979; Bothwell, 1996). Infants, children, and 
adolescents generally have a low serum ferritin concentration between 20 and 30 µg/L since 
most absorbed iron is utilized for growth and development. Ferritin concentrations increase 
in adult males until reaching a plateau of about 100 µg/L by 45 y. However, ferritin remains 
low in adult females until menopause; thereafter serum ferritin concentration gradually rises 
to concentrations comparable with adult men (Cook et al., 1976; Bothwell, 1996). Besides 
age and gender, routine oral contraceptive use may also influence serum ferritin 
concentration (Mooij et al., 1992).  
Serum ferritin concentration may increase independently of iron stores in some 
conditions such as chronic inflammation (Kukulj et al., 2009), infection (Chaiyaratana et al., 
2008), and neoplasia (Hearnshaw et al., 2006). In inflammation/infection, IL-6 mainly 
produced by hepatic Kupffer cells induces hepcidin expression (Ganz, 2003), which then 
blocks iron absorption and release from iron stores, resulting in a low plasma iron and a high 
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serum ferritin concentration. As a result, patients under some conditions may have higher 
serum ferritin but may be actually iron deficient.  
For more complete assessment of iron status, serum ferritin is usually used in 
combination with other indicators reflecting functional iron compartments, such as 
hemoglobin and TfR, especially in populations with low iron stores like young children or 
with other disease conditions (Baynes, 1996).  
Serum Iron, Transferrin Saturation, and Total Iron-binding Capacity 
Serum iron is measured as the iron bound to serum transferrin, an iron transport 
protein. It is usually used in conjunction with transferrin saturation and total iron-binding 
capacity (TIBC) (CDC, 2008). Serum transferrin has two iron-binding sites and normally 
only one third of transferrin is saturated with iron (Crichton, 2006). TIBC measures serum 
transferrin after all available binding sites are saturated with iron; transferrin saturation is 
calculated as the ratio of serum iron to TIBC. TIBC increases with the depletion of storage 
iron and declines in chronic inflammation, infection and malignancies. In iron deficiency, 
serum iron declines but TIBC generally increases (>400 µg/dL), resulting in a low transferrin 
saturation (<16%). In iron overload, transferrin saturation is usually greater than 60%.  
Although serum iron and transferrin saturation are widely used in iron deficiency screening, 
their use is limited by the daily fluctuation of serum iron (CDC, 2008; Zimmermann, 2008).  
Transferrin Receptor 
Transferrin receptor, which reflects tissue iron sufficiency, is a sensitive indicator of 
functional iron deficiency (Skikne et al., 1990) and in differentiating iron deficiency anemia 
from anemia caused by liver injury, inflammation, infection, or malignancy (Ferguson et al., 
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1992; Dimitriou et al., 2000). A quantitative phlebotomy study showed that serum TfR 
increased in proportion to the extent of iron deficiency after the depletion of iron stores 
(serum ferritin <12 µg/L) (Skikne et al., 1990). Therefore, TfR is particularly useful in the 
evaluation of iron status in young children, adolescents, pregnant women, and trained 
athletes who commonly have low iron stores. Although expanded erythroid bone marrow 
may cause elevated TfR without functional iron deficit, these conditions may be 
distinguished from iron deficiency by testing serum ferritin concentration (Baynes, 1996).  
Serum Transferrin Receptor-Ferritin Ratio 
 Since serum ferritin and TfR, respectively, reflect storage iron and functional iron 
deficits, the ratio of serum TfR-to-ferritin has been used to quantitatively estimate total body 
iron in infants (Olivares et al., 2000), children (Malope et al., 2001) or adults (Skikne et al., 
1990; Cook et al., 2003). This ratio is particularly helpful in the calculation of iron absorbed 
over time for intervention trials to improve iron status. The use of this method is limited 
because serum ferritin and TfR concentrations are affected by some disorders independent of 
body iron status. In addition, this ratio is assay specific, since the TfR assay has not been 
standardized (Cook et al., 2003).  
Apart from the TfR-to-ferritin ratio, the TfR-ferritin index (the ratio of serum TfR-to-
log transformed ferritin, TfR-F index) has also proved to be a good indicator of iron 
depletion (Punnonen et al., 1997; Punnonen et al., 1998; Suominen et al., 1998). Punnonen et 
al. (Punnonen et al., 1997) had evaluated the diagnostic efficiency of lab tests for iron 
depletion among 129 consecutive anemic patients [48 with iron deficiency anemia (IDA), 64 
with anemia of chronic disease (ACD), and 17 with depleted iron stores and an infectious or 
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inflammatory condition (COMBI)]. They found that TfR-F index not only had the highest 
sensitivity (the proportion of actual positive values which are correctly identified as positive) 
and specificity (the proportion of negative values which are correctly identified) to identify 
iron depletion out of a variety of indicators, including mean corpuscular volume, serum iron, 
transferrin, ferritin, transferrin saturation, TfR, TfR-to-ferritin ratio, and TfR-F index, but 
also was effective in distinguishing among IDA, ACD, and COMBI.  
Red Blood Cell Indices 
Red blood cell indices can be measured to assess the iron depletion in functional 
compartments, because iron deficiency anemia manifests as microcytic and hypochromic 
anemia with reduced hemoglobin, hematocrit (the proportion of blood volume occupied by 
red blood cells), mean corpuscular volume (MCV), and mean corpuscular hemoglobin 
(MCH). However, the specificity of red blood cell indices is low because microcytic anemia 
can be caused by other conditions, such as lead poisoning, as long as hemoglobin synthesis is 
impaired. In addition, hemoglobin concentration differs with age, sex, and race and is 
affected by smoking, pregnancy and many other factors. Thus, the sensitivity of hemoglobin 
is also low due to the large overlap in values between normal and anemic populations (Cook 
et al., 1971). Since zinc is incorporated into protoporphyrin for hemoglobin synthesis when 
iron is insufficient, erythrocyte zinc protoporphyrin (ZPP) concentration is also a sensitive 
indicator of iron deficiency. Similarly, it is influenced by many factors, such as malaria, 
inflammation, and lead poisoning (Wood & Ronnenberg, 2005; Zimmermann, 2008). 
Another limitation of these indicators is that they become abnormal relatively late in the 
development of functional depletion due to the long survival (~120 days) of red blood cells 
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(Crichton, 2006). Reticulocyte hemoglobin content measures hemoglobin in reticulocytes 
(red blood cells one to two day old) rather than hemoglobin in all red blood cells between 1-
120 days; thus, it is sensitive enough to reflect iron deficient erythropoiesis within days of 
onset. The drawback of this method is that false normal values may be caused by increased 
MCV (Wish, 2006; Zimmermann & Hurrell, 2007). 
Iron Deficiency 
Definition 
Iron deficiency is a functional deficit of iron resulting from depleted iron stores and 
changes in iron metabolism and iron-related biochemical indices. It can be classified into 
latent iron deficiency (LID, iron deficiency without anemia) and iron deficiency anemia 
(IDA) (Wood & Ronnenberg, 2005).  
Prevalence 
 Iron deficiency (ID) is the most prevalent nutritional disorder in the world, affecting 
approximately 2 to 5 billion people globally (Wood & Ronnenberg, 2005).  The prevalence 
of ID is estimated to be ~50% and ~10%, respectively, in developing and developed 
countries (Denic & Agarwal, 2007).  According to the 1999-2000 National Health and 
Nutrition Examination Survey in the United States, ID incidence was high in toddlers aged 1 
to 2 y (7%) and females 12-49 y (9 to 16%) compared to other age and sex groups. 
Additionally, the prevalence of ID is twice as high among non-Hispanic black and Mexican-
American females (19-22%) compared to non-Hispanic white females (10%). Further 
investigation found that overall IDA incidence (Table 3) was around 3% among these 
vulnerable ethnic groups (Looker & Cogswell, 2002).  
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Table 3. Prevalence of Iron Deficiency Anemia in Selected Populations in the United 
States, NHANES 1999-2000* 
Sex/Age group (yrs) No. % (95% CI┼) 
Both sexes    
      1-2 319 2§ (0-4) 
Females¶    
      12-49 1950 3 (2-4) 
          12-19 1001 2 (1-3) 
          20-49 949 4 (2-5) 
      50-69 611 3§ (0.5-5) 
         >70 394 1§ (0-2) 
*All racial/ethnic groups. 
┼Confidence interval. 
§Unreliable; relative standard error (i.e., standard error/prevalence estimate) is >30%. 
¶Nonpregnant only. 
Source: (Looker & Cogswell, 2002) 
Causes 
Primary causes of ID in vulnerable groups are described in Table 4 (Zimmermann & 
Hurrell, 2007; WHO, 2008). People with monotonous plant-based diets with little meat, such 
as vegetarians, are at risk of ID because non-heme dietary iron has low absorption efficiency 
(generally less than 10%). In addition, the absorption of non-heme iron is inhibited by 
phytate, polyphenols and calcium (Zimmermann & Hurrell, 2007), commonly found in 
foods, with phytate being particularly high in the plant-based diets. For example, phytate 
ubiquitously exists in plants including nuts, cereals, legumes, and oilseeds (Weaver & 
Kannan, 2001); polyphenols are present in green and black teas, coffee, fruits, vegetables, 
olive oil, red and white wines (Perron & Brumaghim, 2009). Impaired iron absorption may 
also result in ID. Because non-heme iron absorption is facilitated by gastric acid that helps to 
dissolve and reduce dietary iron (Bezwoda et al., 1978), impaired gastric secretion may 
contribute to ID, as noted in achlorhydria and mucosal atrophy. Atrophic gastritis is common 
in the elderly, thus they are vulnerable to ID. For infants, iron stores accumulated during 
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gestation are soon used very early in life due to rapid growth and ID will develop if iron-
fortified formula/foods are not provided. Similar to infants, young children and early 
adolescents are also at risk of ID because of rapid growth and relatively low body iron stores. 
Premenopausal women are vulnerable to ID primarily due to menstrual iron losses, which are 
estimated to be 0.5 mg iron/ml blood (Harvey et al., 2005). Pregnant women have higher iron 
requirements because of expanded blood volume and fetal growth. In addition, excessive iron 
losses may occur due to increased bleeding with gastrointestinal parasitic infection and some 
gastrointestinal diseases. Thus, patients with these diseases are vulnerable to ID (Herbert, 
1987; Zimmermann & Hurrell, 2007).  
Table 4. Causes of Iron Deficiency 
Primary causes  Vulnerable groups 
Insufficient iron 
intake/absorption 
Low dietary iron intake 
Impaired iron absorption due to 
substances interfering with iron 
absorption, such as phytate or 
phenolic compounds in diets  
Disease conditions like 
achlorhydria, mucosal atrophy  
People in developing country 
Population with monotonous 
plant-based diets with little 
meat and vegetarian based 
diets 
Elder people and patients with 
celiac disease 
High iron 
requirement 
Rapid growth 
 
Pregnancy 
Menstruation  
Infants, children, and 
adolescents 
Pregnant women 
Premenopausal women 
Excessive iron 
losses 
Gastrointestinal parasitic infection 
 
Bleeding from gastrointestinal tract 
caused by diseases 
People in endemic areas of 
parasitic infection  
Patients with gastrointestinal 
diseases  
Source: (Zimmermann & Hurrell, 2007; WHO, 2008) 
Consequences 
IDA has been associated with impaired cognitive and physical development in infants 
and children (WHO, 2001). Even iron deficiency without anemia has a detrimental effect on 
cognition and behavior in infants. Recent studies found that poor iron status (IDA and LID) 
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adversely affected infant motor development and social-emotional behavior in a dose-
dependent manner (Lozoff et al., 2008; Shafir et al., 2008). IDA during pregnancy may result 
in premature delivery and low birth weight (Lee et al., 2006). In addition, maternal iron 
deficiency negatively affected mother-child interactions as reflected by significantly lower 
score on maternal sensitivity and child responsiveness in IDA women than iron sufficient 
women at 10 wk or 9 mo postpartum. Iron supplements (125 mg FeSO4/d) for 9 mo corrected 
the problem (Murray-Kolb & Beard, 2009). Additionally, IDA is associated with fatigue and 
reduced work productivity in adults due to impaired capacity in oxygen transport and 
oxidative metabolism (Haas & Brownlie, 2001; WHO, 2001).  
ID is one of the ten leading risk factors for global burden of disease (impact caused 
by mortality and morbidity; measured by disability-adjusted life year (DALY) combining 
years of life lost due to premature deaths and years of life living in states of less than full 
health). It is estimated that ID causes almost a million deaths per year, accounting for 1.5% 
of deaths worldwide. The DALY resulting from ID is even greater. ID accounts for 2.4% of 
global DALYs. Particularly, one-fifth and one-tenth of perinatal and maternal deaths, 
respectively, in developing countries are attributed to ID (WHO, 2002).  
Diagnosis 
The indicators of ID are shown in Table 5 (Zimmermann & Hurrell, 2007; 
Zimmermann, 2008). ID can be diagnosed if serum ferritin concentration is less than 12 
µg/L. However, serum ferritin may still be high in several conditions independent of iron 
status, as previously mentioned. Therefore, serum ferritin is generally examined to identify 
iron stores in combination with TfR and/or ZPP, considering that TfR and ZPP are sensitive 
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indicators of iron deficiency erythropoiesis, to determine if the reduced erythropoiesis is due 
to iron deficiency (Sherwood et al., 1998). TfR is not influenced by the acute phase response 
(Ferguson et al., 1992; Asobayire et al., 2001), while ZPP increases in ACD and 
myelodysplastic syndromes. TfR is usually <80 µmol/mol heme, not as high as the value 
observed in IDA (>100 µmol/mol heme) (Sherwood et al., 1998). A previous study (Skikne 
et al., 1990) demonstrated that the combination of transferrin receptor and ferritin provided 
an accurate diagnosis (92%) of ID. The specificity and sensitivity of several conventional 
tests are shown in Table 6. In case of combined ID with ACD, a higher cutoff value of serum 
Table 6. Sensitivity and Specificity of Conventional Tests to Identify Iron Deficiency 
Test Cut-off Sensitivity (%) Specificity (%) 
Ferritin <20 µg/L 71 87 
ZPP >100 µmol/mol heme 95 80 
Iron <10 µmol/L 78 40 
TIBC <45 µmol/L 76 90 
Saturation (%)  <15 90 62 
Source: (Sherwood et al., 1998) 
ferritin (such as 60 µg/L) can be used to diagnose ID. Additionally, transferrin saturation 
<15% together with TIBC >70 µmol/L is diagnostic of ID. Other indicators may also be used 
to assist in the diagnosis. Although lead poisoning may result in >1000 µmol/mol heme, 
examination of blood lead along with high ZPP in a patient can quickly confirm the diagnosis 
(Sherwood et al., 1998).  
Iron deficiency is common in developing countries. Severe ID causes anemia and 
results in a number of adverse outcomes. Infants, children, and adolescents are at risk of ID 
due to increased iron requirements. Women at childbearing age are also vulnerable to ID 
because of menstrual iron losses and poor dietary habits. Even in the developed countries, ID 
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is a health problem for women of childbearing age. To improve accuracy, the diagnosis of ID 
is usually achieved by using a combination of several indicators.  
 Table 5. Indicators of Iron Deficiency 
 Selected cutoff values to 
define ID 
Comments 
Hemoglobin (g/L) 6 mo-5 y <110 
6-11 y <115 
Non-pregnant women <120 
Pregnant women <110 
When used alone, it has low specificity and sensitivity. 
Thresholds vary by age, gender, pregnancy, altitude, ethnicity. 
Mean corpuscular 
volume (MCV) (fL) 
Children older than 11 y  
and adults <82  
A reliable, but late indicator of iron deficiency. 
Low values can also be due to thalassaemia and/or inflammation. 
Haematocrit (%) 6 mo-59 mo <0.33 
5-11 y <0.34 
12-14 y <0.36 
Non-pregnant women <0.36 
Pregnant women <0.33 
Men >15 y <0.39 
Same as hemoglobin 
Reticulocyte 
haemoglobin content 
(CHr) (pg) 
In infants and young  
children <27.5 
In adults <28.0 
A sensitive indicator that falls within days of onset of iron-deficient 
erythropoiesis. 
False normal values can occure when MCV is increased and in thalassaemia. 
Wider use is limited because it can only be measured on a few models of 
analyser. 
Erythrocyte zinc 
protoporphyrin 
(ZPP) (µmol/mol 
haem) 
5 y or younger >70 
Children older than 5 y >80 
Children older than 5 y on 
washed red cells >40 
It can be measured directly on a drop of blood with a portable 
haematofluorometer. 
A useful screening test in field surveys, particularly in children, in whom 
uncomplicated iron deficiency is the primary cause of anaemia. 
Red cells should be washed before measurement because circulating factors, 
including serum bilirubin, can spuriously increase values. 
Lead poisoning can increase values, particularly in urban and industrial settings. 
Serum or plasma 
iron (µg/L) 
<40-50 Varies diurnally and after meals. 
Low values in chronic disease. 
Transferrin 
saturation 
<16% It is inexpensive, but its use is limited by diurnal variation in serum iron and by 
many clinical disorders that affect transferrin concentrations. 
Serum or plasma 
total iron binding 
capacity (µg/dL) 
>400 Large overlap between normal values and values in iron deficiency. 
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 Table 5. (continued)  
Serum transferrin 
receptor (sTfR) 
Cutoff varies with assay, and 
with patient age and ethnic 
origin 
Main determinants are erythroid mass in bone marrow and iron status; thus, 
sTfR is increased by enhanced erythropoiesis and iron deficiency. 
sTfR is not substantially affected by the acute-phase response, but it might be 
affected by malaria, age, and ethnicity. 
Its application limited by high cost of commercial assays and lack of an 
international standard. 
Serum ferritin (SF) 
or plasma ferritin 
(µg/L) 
5 y or younger <12 
Children older than 5 y <15 
In all age groups in the 
presence of infection <30 
It is probably the most useful laboratory measure of iron status; a low value of 
SF is diagnostic of iron deficiency anaemia in a patient with anemia. 
In healthy individuals, SF is directly proportional to iron stores: 1 µg/L SF 
corresponds to 8-10 mg body iron or 120 µg storage iron per kg body weight. 
As an acute-phase protein, SF increases independent of iron status by acute or 
chronic inflammation; it is also unreliable in patients with malignancy, 
hyperthyroidism, liver disease, or heavy alcohol intake. 
sTfR-to-SF ratio  This ratio is a quantitative estimate of total body iron; the logarithm of this ratio 
is directly proportional to the amount of stored iron in iron-replete patients and 
the tissue iron deficit in iron deficiency. 
In elderly people, this ratio might be more sensitive than other laboratory tests 
for iron deficiency. 
This ratio cannot be used in individuals with inflammation because SF might be 
high independent of iron stores. 
This ratio is assay specific. 
Although it is only validated for adults, this ratio has been used in children. 
Body iron stores 
(mg/kg weight): [log 
(TfR/ferritin ratio)-
2.8229]/0.1207 
Negative values indicate 
tissue iron deficit 
Cannot be used in individuals with inflammation because the SF may be 
elevated independent of iron stores. 
Is assay specific 
Although only validated for adults, is often used in children. 
 Source: (Zimmermann & Hurrell, 2007; Zimmermann, 2008)
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II. ZINC METABOLISM 
Importance of Zinc 
As an essential nutrient for human health, zinc plays an important role in normal 
growth and development (Gardner et al., 2005; Islam et al., 2009), immune function (Ibs & 
Rink, 2003), as well as reproduction (Bedwal & Bahuguna, 1994) by either participating in 
enzyme function and gene regulation or maintaining protein structure and stability. For 
example, more than 300 enzymes require zinc for their catalytic activity and the expression 
of metallothionein (MT, protein important in maintaining oxidoreductive homeostasis) is 
induced by the binding of zinc to the metal response element transcription factor (MTF1) 
(McCall et al., 2000; King & Cousins, 2005).  Zinc deficiency could result in impaired 
immune function (Prasad, 2008), delayed growth, and increased susceptibility of respiratory 
infection, malaria, and diarrheal disease (WHO, 2002).  Additionally, zinc supplementation 
improved growth in children and infants (Lind et al., 2004; Mozaffari-Khosravi et al., 2009), 
reduced malarial episodes (Zeba et al., 2008), and the duration/incidence of diarrhea (Baqui 
et al., 2002; Roy et al., 2007), suggesting the importance of zinc.  
Body Zinc Distribution 
The human body contains approximately 1.5-2.5 g zinc, making it the second most 
abundant trace mineral in the body, only slightly lower than iron (King & Cousins, 2005). As 
described in Table 7 (Rink & Gabriel, 2000), muscle and bone account for the majority of 
body zinc. However, some organs such as the prostate also have high concentrations of zinc 
and erythrocytes contain 15~30 mg zinc. In addition, most (95%) of the body zinc is 
intracellular, primarily existing in the cytosol (King & Cousins, 2005).     
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Table 7. Zinc Content of Human Organs 
Organ Zn Content µg/g organ dry weight % whole-body Zn 
Skeletal muscle 51 57.0 
Bone  100 29.0 
Skin 32 6.0 
Liver  58 5.0 
Brain  11 1.5 
Kidney  55 0.7 
Heart  23 0.4 
Hair  150 0.1 
Plasma  1 0.1 
Source: (Rink & Gabriel, 2000) 
Zinc Absorption, Regulation, and Distribution 
Zinc is absorbed in the small intestine primarily through an active saturable process. 
It is transported into enterocytes by ZIP4 (Zrt/Irt-like protein 4) and ZNT5 (zinc transporter 
5) and then is exported into circulation by another zinc transporter ZNT1 (Lichten & 
Cousins, 2009). As zinc concentration in the intestinal lumen exceeds the capacity of active 
transport, zinc diffuses directly into circulation through the tight junctions between 
enterocytes (Grider, 2006). Circulating zinc is then delivered to cells primarily by albumin 
for utilization (Figure 4) (King & Cousins, 2005). Surplus zinc can be stored in bone and 
spleen (Emsley, 2001). Previous studies have found rapid zinc turnover (about 12.5 d) in the 
liver, pancreas, kidney and spleen and slow zinc turnover (about 300 d) in muscle, red blood 
cells, bone and nervous system. Zinc is recycled from senescent erythrocytes similar to iron 
through the reticuloendothelial system (King & Cousins, 2005). Zinc excretion is mainly 
through feces (90%; from pancreatic and biliary secretions, gastroduodenal secretions, and 
transepithelial flux from enterocytes (Krebs, 2000)), urine (5%), and sweat (5%) (Emsley, 
2001; Alpers et al., 2008). Other zinc losses include epithelial cell desquamation, semen, 
26 
 
menstruation, parturition, and lactation (Food and Nutrition Board & Institute of Medicine, 
2000). 
Zinc homeostasis can be generally maintained through adjustments in zinc absorption 
and endogenous intestinal excretion as well as other changes (King et al., 2000; King & 
Cousins, 2005). Zinc absorption adjusts in response to the individual’s zinc status (King & 
Cousins, 2005), dietary zinc content (Chung et al., 2008), and the bioavailability of soluble 
zinc (influenced by many dietary enhancers or inhibitors) (Lonnerdal, 2000; Hunt et al., 
2008). For example, a group of Korean women was found to have lower zinc absorption 
(22% vs 43%) when consuming a diet high in phytate compared to a low phytate diet (Kim et 
al., 2007). In addition, dietary zinc is positively related to fecal zinc losses (King & Cousins, 
2005). It was reported that 25 d of dietary zinc deprivation (from 85 µmol/d to 12 µmol/d) 
with healthy male subjects (n=4) resulted in significantly reduced fecal and urinary zinc 
losses with no significant change in plasma zinc concentration (Taylor et al., 1991). 
Additionally, zinc homeostasis is regulated by MT. When intracellular zinc concentration is 
high, zinc binds to MTF1 and activates MT, which in turn sequesters zinc to reduce the 
intracellular zinc concentration (Lichtlen & Schaffner, 2001). It was also reported in rats that 
intestinal MT synthesis was induced by a high zinc diet but inhibited by a low zinc diet 
(Hempe & Cousins, 1992).   
Zinc absorption is affected by many dietary factors, with animal protein acting as 
promoter and phytate and calcium as inhibitors (Krebs, 2000). Phytate reduces zinc 
absorption by binding to zinc and forming poorly soluble complexes. The molar ratio of 
phytate-to-zinc is usually used to assess zinc bioavailability and absorption. Diets with a 
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molar ratio <5 have high availability and the absorption is around 50% when dietary zinc 
intake meets the body requirement. At molar ratios between 6 and 10, zinc absorption begins 
to decline; when the ratio exceeds 15 as is the case with soy products, zinc availability is low 
and the absorption is typically lower than 15% (Sandström, 1989; FAO/WHO, 2004). 
Generally, 3-4 mg zinc is absorbed from the intestine per day with an average 
efficiency of 30-40% based on 15 mg of dietary zinc intake (King & Cousins, 2005; Alpers 
et al., 2008). Based on 7-15 mg intake, about 3.0-4.6 mg of zinc is lost per day (King & 
Cousins, 2005).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Schematic of Zinc Kinetics  
Source: (King & Cousins, 2005) 
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Zinc Requirements 
The dietary zinc requirement has been estimated based on a factorial approach, in 
which total zinc requirement for tissue growth, maintenance, metabolism, and endogenous 
losses was divided by an average fractional absorption value in the population (King & 
Cousins, 2005). Table 8 (Food and Nutrition Board & Institute of Medicine, 2000) indicates 
the dietary reference intakes for zinc. 
Table 8. Dietary Reference Intake for Zinc 
 DRI (mg/d) 
Infants  
    0-0.5 yr 2 (AI) 
    0.5-1 yr 3 
Children  
    1-3 yr 3 
    4-8 yr 5 
    9-13 yr 8 
Males  
    >14 yr 11 
Females  
    14-18 yr 9 
       Pregnant 12 
       Lactating  13 
    >19 yr 8 
       Pregnant 11 
       Lactating  12 
Source: (Food and Nutrition Board & Institute of Medicine, 2000) 
Dietary Zinc Intake 
According to NHANES III in the United States, the median dietary zinc intake ranged 
from 5.4 mg in non-breastfeeding infants to 9-11 mg in adolescents and adults. Most infants 
and more than half of the males aged 4-70 y met the recommended dietary allowance (RDA) 
of zinc, but only 18.9% of young children aged 1-3 y, 39% of female adolescents, and 44% 
of male elderly aged >71 y satisfied their RDA (Briefel et al., 2000).  
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Lean red meat, whole grain cereals, pulses, and legumes are the best dietary sources 
of zinc providing 25-50 mg/kg. Processed cereals with low extraction rates, polished rice, 
chicken, pork, or meat with a high fat content are also good sources of zinc with 10-25 mg/kg 
(FAO/WHO, 2004). However, due to the presence of phytate (a dietary inhibitor of zinc 
absorption), grains and plant foods have lower zinc bioavailability than animal foods (FNB & 
IOM, 2000). The zinc content of fish, green leafy vegetables, and fruits is low with <10 
mg/kg (FAO/WHO, 2004). Globally, pulses and cereals are the major zinc sources. However, 
in the US, they account for 30% of dietary zinc. Meat and dairy products, respectively, 
provided 50% and 20% of dietary zinc (Maret & Sandstead, 2006).  
Assessment of Zinc Status 
No reliable and accurate indicators are available to reflect individual zinc status. 
Daily zinc losses can be estimated from fecal zinc excretion, but this method is cumbersome 
and not routinely used. When zinc deficiency is suspected based on the evidence from low 
dietary intake, poor bioavailability, or suggestive clinical signs, definitive diagnosis can be 
reached by a symptomatic response after zinc supplementation. However, this method is 
limited by cost and time requirement (King & Cousins, 2005; Alpers et al., 2008).   
Plasma Zinc 
Plasma zinc is widely used as the screening test, although it is a relatively insensitive 
indicator of zinc status. Plasma zinc concentration is generally stable but decreases after 
several weeks of severe dietary restriction when tissue zinc concentrations are reduced. Thus, 
it poorly reflects tissue zinc status and cannot be used to identify marginal zinc deficiency. In 
addition, it is affected by other conditions independent of zinc status. For example, plasma 
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zinc concentration declines after food intake and in stress situations, such as fever and 
infection. In contrast, hemolysis and long-term fasting increase plasma zinc concentration 
(Alpers et al., 2008). However, reduced plasma zinc concentration may indeed be indicative 
of zinc-responsive growth reduction in a population (FAO/WHO, 2004). Serum zinc 
concentration can also be measured to assess zinc status, but false elevation may occur due to 
contamination (FNB & IOM, 2000).  
Lymphocyte Zinc Content 
Zinc status can be assessed by measuring lymphocyte zinc content (Terwolbeck et al., 
1992). This method has been reported to be sensitive to marginal zinc intake in small, well-
controlled studies. However, the effectiveness has not been verified in larger groups and the 
difficulty in separating white blood cells limits its utilization (Grider, 2006). In addition, this 
method needs a relatively large amount of blood sample, also limiting its utilization in small 
children (Eaton et al., 2004).  
Hair Zinc Concentration 
Hair zinc concentration is sensitive in detecting marginal zinc deficiency in children 
in the absence of protein-energy malnutrition. However, factors such as age, sex, and hair 
growth rate must be considered in the interpretation of results (Gibson et al., 2008). Besides, 
normal hair zinc concentration does not rule out zinc deficiency due to the possible 
contamination from shampoo (Eaton et al., 2004).  
Functional Indicators 
 Functional changes in growth, body composition, cell-mediated immunity, 
neurological performance/recognition, neuromotor function, dark adaptation, taste, and smell 
31 
 
acuity may be observed well before the reduction in plasma zinc in zinc deficiency. Hence, 
symptomatic response after zinc supplementation is useful in the diagnosis of zinc 
deficiency. Well controlled observation is necessary when using these functional indicators 
because they are not specific for zinc deficiency (Maret & Sandstead, 2006).  
Other Indicators  
Urinary zinc excretion declines in severe zinc deficiency (FAO/WHO, 2004) and 
responded quickly after dietary zinc changes (Ruz et al., 1991). Thus, urinary zinc is also 
used as a marker for zinc status, but it is affected by diseases independent of zinc status, such 
as renal disease. Muscle biopsy is another method to assess zinc status but it is invasive and 
samples may be contaminated by fat, collagen, or blood (Eaton et al., 2004). Additionally, 
zinc status may be assessed by measuring erythrocyte zinc, MT (Grider et al., 1990; 
Caulfield et al., 2008) or zinc-dependent enzymes, such as serum alkaline phosphatase 
(Rothbaum et al., 1982; Samman et al., 1996).  
Zinc Deficiency 
Zinc deficiency is a condition where inadequate zinc is available for metabolic needs. 
It is usually nutritional in origin but may also be secondary to conditions such as 
malabsorption syndrome and chronic liver disease (Prasad, 2003).  
Prevalence 
Due to the lack of suitable biomarkers for zinc status, the prevalence of zinc 
deficiency has not been adequately investigated (Hambidge, 2000). Based upon food 
availability data, zinc deficiency is estimated to affect one-third of the world population with 
an average prevalence of 31% globally, ranging from 4% to 73% across the WHO subregions 
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(WHO, 2002; Caulfield & Black, 2004). In North America where the mean daily per capita 
zinc intake is estimated to be ~11-12 mg and more than half of the zinc is from animal 
sources (Brown et al., 2001), apparent zinc deficiency is uncommon (Food and Nutrition 
Board & Institute of Medicine, 2000).  
Causes 
Primary causes of zinc deficiency are inadequate dietary intake or low absorption, but 
also include excessive zinc losses. Individuals mainly with plant-based diets, such as 
vegetarian and people in impoverished areas, are at risk of zinc deficiency. Although their 
Table 9. Causes of Zinc Deficiency 
Primary causes  Vulnerable groups 
Insufficient 
intake/ Low 
bioavailability 
Low zinc-containing diets: foods poor in 
animal protein 
Diet high in absorption inhibitors such as 
phytate and fibers 
Shortage of nutrient intake  
Loss of zinc during food processing 
(desalting during production of artificial 
milk, etc.)  
Prolonged intravenous/enteral 
alimentation 
Vegetarians 
Low income people 
Patients fed intravenously  
without zinc 
supplementation 
 
Impaired 
absorption 
Drugs with chelating activity such as 
EDTA, penicillamine 
 
 
Disease conditions  
Individuals with 
malabsorption syndrome 
and acrodermatitis 
enteropathica, etc.  
Elderly 
High 
requirement 
Rapid growth and development 
Pregnancy 
Infant, children, adolescents 
and pregnant women  
Excessive 
losses 
Loss into digestive fluid;  
Increased urinary elimination; 
Burns and hemodialysis 
Patients with diarrhea, 
chronic diseases such as 
liver cirrhosis and renal 
insufficiency etc. 
Unexplained 
reasons 
Congenital thymus defect 
Down’s syndrome 
 
Source: (Yanagisawa, 2008) 
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dietary zinc intake may be adequate, the amount of zinc absorbed may be not sufficient due 
to the presence of inhibitors, such as phytate and fiber from plant products (Caulfield & 
Black, 2004). A long-term crossover study reported that consuming a lactoovovegetarian 
diets (molar ratio of phytate-to-zinc=14) for 8 wk reduced zinc absorption by 35% and 
plasma zinc concentration by 5% in women (n=22) (Hunt et al., 1998). Infants, children, 
adolescents and pregnant women are also vulnerable to zinc deficiency due to increased zinc 
demand for rapid growth (FAO/WHO, 2004). Additionally, zinc deficiency may result from 
impaired zinc absorption, excessive zinc losses, and/or unknown causes as described in Table 
9 (Yanagisawa, 2008).  
Consequences 
Zinc deficiency causes growth retardation in infants (Islam et al., 2009), children, and 
adolescents (Nishi et al., 1989; Siklar et al., 2003), and negatively affects sexual 
development in adolescents (Fons et al., 1992). Maternal intake of zinc during pregnancy and 
lactation was reported to be negatively associated with neonate focused attention and infant 
motor performance (Kirksey et al., 1994). Maternal zinc deficiency may result in a number 
of adverse outcomes including spontaneous abortion, congenital malformations, low birth 
weight/intrauterine growth retardation and preterm delivery (Wells et al., 1987; Jameson, 
1993). Additionally, zinc deficiency impairs cognitive function in pregnant women (Stoecker 
et al., 2009) and psychological dimensions in the elderly (Marcellini et al., 2006). It also 
compromises immune function by affecting all types of immune cells (Ibs & Rink, 2003).  
Zinc deficiency is significant cause of respiratory infections, malaria, and diarrheal 
disease. Out of twenty leading risk factors for diseases in the world, zinc deficiency ranks 
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11th. It contributes to 16% of lower respiratory tract infections, 18% of malaria, 10% of 
diarrheal disease, and 1.4% (0.8 million) of deaths (1.4% for male and 1.5% for female). 
Approximately 2.9% (28 million) of DALYs in the world are attributed to zinc deficiency 
(WHO, 2002). Among children between 6 mo and 5 y, zinc deficiency was responsible for 
14.4% diarrheal deaths, 10.4% malarial deaths and 6.7% pneumonia-related deaths, 
contributing to 4.4% of childhood deaths (453207 deaths) and 3.8% of disease burden in 
Latin America, African, and Asia in 2004 (Fischer Walker et al., 2008).  
Diagnosis 
Zinc deficiency is suspected in cases of low dietary zinc intake, poor zinc 
bioavailability and absorption or suggestive clinical signs as indicated in Table 10 (King & 
Cousins, 2005). To diagnose zinc deficiency, a number of lab indicators (described in 
assessment of zinc status section) and a symptomatic response with zinc supplementation are 
usually monitored (Roth & Kirchgessner, 1999; King & Cousins, 2005; Alpers et al., 2008). 
Zinc-binding capacity and serum/plasma alkaline phosphatase activity prior to and after zinc 
Table 10. Clinical Manifestation of Marginal to Severe Human Zinc Deficiency 
Growth retardation 
Delayed sexual maturation and impotence 
Hypogonadism and hypospermia 
Diarrhea and intestinal inflammation 
Alopecia  
Acroorificial skin lesions 
Other epithelial lesions: glossitis, alopecia, nail dystrophy 
Immune deficiencies: lymphopenia, thymic defects, reduced phagocytosis,  
    depressed T-cell function, impaired cytokine production 
Behavioral disturbances, including impaired hedonic tone 
Impaired taste (hypogeusia) 
Delayed healing of wounds, burns, and decubitus ulcers 
Impaired appetites and food intake 
Eye lesions, including photophobia and lack of dark adaptation and photic injury 
Source: (King & Cousins, 2005) 
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supplementation (zinc tolerance test) are considered to be most useful lab parameters (Roth 
& Kirchgessner, 1999). Sweat mineral analysis was not only non-invasive, convenient, and 
repeatable, but also more sensitive than blood or hair analysis. Thus, sweat mineral analysis 
may be suitable in clinical practice for auxiliary diagnosis of marginal zinc deficiency.  
Similarly, Bryce-Smith taste test has also been suggested as useful in the diagnosis of zinc 
deficiency, although not as accurate as sweat mineral analysis (Eaton et al., 2004).  
Zinc deficiency is prevalent in developing countries. It has been associated with a 
number of adverse consequences, since zinc is an essential nutrient for human health. The 
primary causes of zinc deficiency are insufficient zinc intake and low zinc absorption. 
Apparent zinc deficiency is not common in the western world, whereas marginal zinc 
deficiency may be a problem. Infants, children, adolescents and pregnant women are 
vulnerable to zinc deficiency due to increased zinc demand. No completely reliable and 
accurate indicators are available to reflect individual zinc status, but diagnosis of zinc 
deficiency can be achieved by examining the symptomatic response to zinc supplementation.  
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III. SOY CONSUMPTION 
Soy Foods and Soy Components  
Soy (soybean), belonging to the leguminous family, constitutes a major component of 
the Asian diet. It has been used in various forms, such as soy milk, tofu, miso, yuba, and 
tempeh (Fournier et al., 1998). In the American diet, except for tofu and soy milk, soy 
products such as soy flour, soy protein concentrate, and soy protein isolate are generally used 
as the primary ingredient of many meat and dairy substitutes. Soy food consumption is not so 
common in the US except for vegetarians and infants consuming soy formula (Erdman & 
Fordyce, 1989). Average daily intake of protein from soy foods is approximately 20-80 g for 
Asians and 1-3 g for Americans (Fournier et al., 1998).  
Soy protein offers almost a complete protein profile with an adequate amount of 
essential amino acids based upon ideal patterns published by the Food and Nutrition Board or 
the Food and Agriculture Organization. Only the sulfur-containing amino acids methionine 
plus cystine in most soy proteins are lower than the recommended amount (Erdman & 
Fordyce, 1989).  Although the protein quality of soy is comparable to that of animal sources 
such as egg, milk and beef, the supplementation of methionine in soy protein products is 
necessary for infants and children (de Oliveira et al., 1981; Fomon et al., 1986) but not for 
adults (Wayler et al., 1983; Young et al., 1984; Endres, 2001).  
Soy products not only provide an excellent source of protein, but are also rich in 
fibers and phytochemicals including isoflavones, phytate, and saponins (Mota et al., 2007). 
For example, soybean or soy products generally contain 1-3% phytate by weight (Anderson 
& Wolf, 1995) and soybean contains about 0.6-6.5% saponins by weight (Berhow et al., 
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2006). However, it is important to note that soy products differ in their chemical composition 
(nutrients and bioactive components) due to various processing techniques. These differences 
make the interpretation and comparison of study data difficult, because traditional soy foods 
derived from whole or dehulled soy beans, such as tofu and soy milk, are generally examined 
in epidemiological studies, while soy concentrates, soy protein isolates, and isolated soy 
isoflavones are used in most animal and human intervention studies (Erdman et al., 2004). 
Dehulling, flaking, defatting, fermenting, and alcohol-washing result in lower isoflavone 
content than the native form of soy products. For example, soybeans contain 2-5 mg 
isoflavones per gram protein, higher than isolated soy protein; soy milk and tofu contain 2 
mg isoflavones per gram protein; the isoflavone content of non-fermented soy foods, such as 
roasted soybeans, is 2-3 times as high as fermented soy foods, such as tempeh and miso 
(Wang & Murphy, 1994).  
Health Effects of Soy Consumption 
Potential Benefits with Soy Consumption 
Cardiovascular Diseases 
The beneficial effect of soy food consumption on cardiovascular disease (CVD) has 
been reported in epidemiological studies. The incidence of CVD in Asian populations who 
commonly consume soy foods has proven to be lower than in Western populations who 
rarely consume soy foods (Beaglehole, 1990). The substitution of animal products with soy 
foods resulting in low-fat, cholesterol-free, and high fiber diets generally leads to a 
hypocholesterolemic response (Carroll et al., 1979). A Japanese study showed an inverse 
association between soy food intake (soy, bean, miso soup) and the risk of cerebral and 
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myocardial infarction as well as CVD mortality in postmenopausal women (Kokubo et al., 
2007).           
Isoflavones in soy may also favorably affect lipoprotein profile, blood pressure, and 
oxidative stress (Djuric et al., 2001) to protect against CVD. The WHO-CARDIAC study 
demonstrated that coronary heart disease mortality rate was positively related to serum 
cholesterol concentrations but inversely related to 24-hr urinary isoflavone excretion 
(Yamori, 2000). A five-wk double-blind dietary intervention with middle-aged men at risk 
for CVD resulted in significant reductions in systolic blood pressure (BP), diastolic BP, total 
cholesterol (TC) and non-high density lipoprotein cholesterol in the soy group (soy powder 
containing at least 20 g soy protein and 80 mg isoflavones per day) compared to no changes 
in placebo group (Sagara et al., 2004). The TC and LDL-cholesterol lowering effect of soy 
isoflavones in mildly hypercholesterolemic individuals has been reported in a dose-
dependent manner (Crouse et al., 1999), and this dose-dependent effect has been also 
supported by a meta-analysis study (Reynolds et al., 2006).  
However, not all studies found beneficial effects of soy on lipoprotein profile. For 
example, another meta-analysis study did not show an improvement in TC and LDL-
cholesterol in normocholesterolemic menopausal women with 1-3 mo ingestion of soy 
isoflavones (about 70 mg/d) (Taku et al., 2008), and two randomized controlled trial with 6 
mo or 6 wk treatment did not observe effects of isoflavones on lipid profile in 
postmenopausal women (Engelman et al., 2005; Rios et al., 2008).  
Other soy components such as phytate may also play a role in decreasing the risk of 
CVD. Phytate was found to reduce platelet aggregation (Vucenik et al., 1999), oxidative 
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stress (Porres et al., 1999) and hepatic/blood lipids (Onomi et al., 2004), though data are 
limited in humans. A 6-wk feeding study found significantly reduced total homocysteine 
concentration (a CVD risk factor) in postmenopausal women after daily consumption soy 
protein with native phyate and low isoflavones (40 g soy protein with 0.64 g phytate and 1.2 
mg isoflavones) but not soy protein with native isoflavones and low phytate (40 g soy protein 
with 0.22 g phytate and 85.8 mg isoflavones), suggesting that phytate is another factor in soy 
that may reduce atherosclerotic CVD risk factors in postmenopausal women (Hanson et al., 
2006).  
Bone Health 
Numerous epidemiological studies have shown beneficial effects of soy food 
consumption on bone. An observational study in Japan reported a positive association of soy 
food consumption with bone mass in postmenopausal women (Somekawa et al., 2001). A 
prospective cohort study in China observed an inverse association between soy food intake 
and bone fracture incidence in postmenopausal women (Zhang et al., 2005). A 2-y 
longitudinal study in young Korean women showed a positive change in bone mineral 
density with soybean consumption (Song et al., 2008). The improvement in bone after soy 
consumption is attributed to soy isoflavones and protein fraction of soy.  
Soy isoflavones have shown to attenuate bone loss. A 6-mo randomized controlled 
trial (RCT) with postmenopausal women (n=30 subjects/group with 0, 84 or 126 mg 
isoflavones per day) found a significant dose-dependent effect of soy isoflavones on 
attenuating bone loss at the lumbar spine and femoral neck (Ye et al., 2006). This study 
indicated that the effect may be via the inhibition of bone resorption as reflected by lower 
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urinary total deoxypyridinoline (Dpyr, a bone resorption marker) excretion in the high dose 
group. Moreover, a meta-analysis based on nine long-term RCT (n=432) showed that the 
consumption of soy isoflavones significantly decreased urinary Dpyr concentration and 
increased serum bone alkaline phosphatase (BAP, a bone formation marker) concentration in 
peri- or postmenopausal women, compared with placebo treatment (Ma et al., 2008).  
However, not all studies observed an effect of soy isoflavones on bone resorption or 
formation. For instance, significantly positive effect on lumbar spine bone mineral density 
and content was found in perimenopausal women with 24 wk intake of isoflavone-rich soy 
but not in those consuming isoflavone-poor soy or whey protein in another study (Alekel et 
al., 2000). However, no effect of soy isoflavones on bone resportion or formation was 
observed in the same study.  
Additionally, some researchers had indicated that soy protein may protect against 
osteoporosis by inducing less urinary calcium excretion than animal protein due to the lower 
content of sulfur-containing amino acids in soy protein (Remer & Manz, 1994). Despite 
similar dietary calcium intakes, a meat-based diet caused significantly higher urinary and 
fecal calcium excretion than a soy-based diet (urine: 127 vs. 88 mg/d; fecal: 467 vs. 284 
mg/d) (Pie & Paik, 1986). 
Despite of positive results from some studies, effects of soy on bone are still 
inconclusive and controversial. For example, 2-y consumption of soy plus isoflavones (25 g 
soy protein with 90 mg isoflavones) was not found to favorably affect bone mineral density 
of lumbar spine and femoral neck, compared to milk protein (25 g casein and whey), in 
postmenopausal women (n=203) (Vupadhyayula et al., 2009). A recent meta-analysis (Liu et 
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al., 2009) of 10 RCTs did not find a significant increase in bone mineral density at lumbar 
spine, total hip or femoral neck in women (n=896) with at least 1 y isoflavone 
supplementation, and the author proposed that the benefit of soy isoflavone supplementation 
on bone health may only be transient, but not long-term.  
Other Possible Health Benefits 
Soy consumption may lower the risk of breast cancer as shown in numerous 
epidemiological studies. For example, a recent prospective cohort study (7.4 y) in China with 
73,223 women reported a substantially reduced risk of premenopausal breast cancer with soy 
food intake (Lee et al., 2009). Similar results were found in another population-based case-
control study, demonstrating the strongest protective effect for early-life soy intake (Korde et 
al., 2009). Additionally, soy food intake may protect against prostate cancer (Kurahashi et 
al., 2007; Yan & Spitznagel, 2009). These protective effects may be attributable to soy 
isoflavones, which have been shown to exert both anti-estrogenic and anti-carcinogenic 
properties. The regulation of cell proliferation and apoptosis in cancer cell lines by soy 
isoflavones has been demonstrated in a number of in vitro studies (Vinall et al., 2007; Imhof 
& Molzer, 2008; Singh-Gupta et al., 2009).  
Soy formula has been shown to be hypoallergenic compared to cow’s milk. The 
incidence of food allergy was lower in infants fed soy formula (3-4% vs 25%) than those fed 
cow’s milk (Cantani & Lucenti, 1997). In addition, the beneficial effect of soy on glycemic 
control in type 2 diabetic patients has been reported (Jayagopal et al., 2002; Shahbazian et 
al., 2007). The glycemic response to soy foods may be attributable to their soluble fiber 
content (Mahalko et al., 1984; Thomas et al., 1988) and soy isoflavones, reported to inhibit 
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intestinal glucose update (Vedavanam et al., 1999) and stimulate insulin secretion (Jonas et 
al., 1995) in animals.   
Potential Risks with Soy Consumption 
Soy Allergy 
Although soy formula has been successfully used in managing cow’s milk intolerance 
in infants, soy protein is one of the eight most significant food allergens listed by the Food 
and Agriculture Organization (FAO, 1995). A double-blind study found that 14% of children 
with IgE-associated cow’s milk allergy (CMA) developed a soy allergy after consuming soy 
formula for a year (Zeiger et al., 1999).  
Mineral Balance   
The concern related to mineral balance mainly focuses on negative effect of phytate 
on mineral bioavailability, because soy or soy products contain significant amount of phytate. 
Phytate binds to multivalent cations, especially zinc, iron, and calcium, and forms insoluble 
complexes in the small intestine, thereby decreasing their bioavailability (Zhou & Erdman, 
1995). It is difficult to evaluate the effect of soy consumption on calcium balance since 
phytate inhibits calcium absorption, but soy protein consumption tends to facilitate urinary 
calcium retention compared to meat protein (Pie & Paik, 1986). Therefore, the effect of soy 
consumption on iron and zinc status is the focus of the following section. 
Iron bioavailability has been demonstrated to not only be extremely poor in pure soy 
foods (Cook et al., 1981), but also poor in mixed diets incorporated with soy foods (Cook et 
al., 1981; Hallberg & Rossander, 1982; Morck et al., 1982). For instance, when full fat soy 
flour, textured soy flour, or isolated soy protein were substituted for egg albumin in a liquid 
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diet, the absorption reduced from 5.5% to 1%, 1.9%, and 0.4%, respectively (Cook et al., 
1981). In a mixed diet with beef and soy flour (1:1), iron absorption was 2-fold lower than in 
a beef only diet (Lynch et al., 1985). Dephytinization improved iron absorption by four- to 
five-fold, but was still only half of the egg control in a single meal study. These results not 
only confirm the inhibitory effect of phyate, but also suggest the existence of dietary 
inhibitors in soy other than phytate (Hurrell et al., 1992).  
Although iron absorption with soy is observed to be low in single meal studies, not all 
long-term feeding interventions reported a negative effect on iron status.  Daily consumption 
of 40 g soy protein isolate for 6 mo showed no adverse effects on iron status in 
perimenopausal women with normal or compromised iron status (Swain et al., 2002).  On the 
contrary, the same amount of protein for 6-wk negatively affected iron status in 
postmenopausal women who had moderately elevated iron stores (Hanson et al., 2006). 
Another 1 y feeding study also did not find significant differences on iron status in infants 
fed with a soy formula or an extensively hydrolyzed whey formula (Seppo et al., 2005). 
Since iron absorption is inversely related to iron status of individuals, the discrepancy of 
these results indicates that the effect of soy foods on iron balance may depend upon the iron 
status of individuals, the protein sources and duration of intervention. 
Soy protein-based diets are generally considered to have low zinc bioavailability due 
to the high phytate-to-zinc molar ratio. For example, when cow’s milk had the same phytate-
to-zinc molar ratio as soy formula after the addition of phytate, zinc absorption was reduced 
two-fold and became similar to the absorption from soy formula (Lonnerdal et al., 1984). 
The inhibitory effect of soy products on zinc absorption is apparent when soy is the sole 
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protein source, but is marginal in mixed diets in the presence of other protein sources, such as 
milk and meat (Solomons et al., 1982; Sandstrom et al., 1987). For example, zinc absorption 
was not significantly affected when milk proteins were substituted with 50% soy (Solomons 
et al., 1982). Similar to iron, zinc absorption was also improved after dephytinization, as 
reflected by increased zinc absorption from 11.3% to 20.1%, but was closer to 31.2% from 
cow’s milk in a single meal study (Zhao et al., 2003). The fact that human adaptation in zinc 
absorption with a low-zinc diet was absent if dietary phytate was high (Hunt et al., 2008), 
also emphasized the importance of dephytinization.  
Due to the lack of a sensitive clinical indicator to assess zinc status, long-term feeding 
studies to assess the effect of soy on zinc balance are limited. Daily consumption of soy 
based diet for 3 mo (70 g soy protein/d) was reported to cause a negative zinc balance and a 
reduction in plasma (25%) and neutrophil (31%) zinc concentrations in a small group (n=5) 
of human subjects (Cossack & Prasad, 1982). Similar results were found in another study 
with daily consumption of a soy protein based diet (57 g soy protein/d) for 28 weeks in male 
subjects (n=5) (Rabbani et al., 1987). However, no effect of soy intake (0.8 g soy protein/kg 
weight) on zinc absorption or balance was found in another long-term (82 days) feeding 
study (Istfan et al., 1983).  
Anti-Thyroid Effect  
Soy consumption may have anti-thyroid effects, especially among those with 
inadequate intake of iodine. Before soy formula was supplemented with iodine in the mid 
1960s, soy-induced goiter had been reported in infants fed with soy formula (Van Wyk et al., 
1959; Hydovitz, 1960; Ripp, 1961). Feeding soy formula to infants with congenital 
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hypothyroidism resulted in prolonged increase in thyroid-stimulating hormone (TSH) 
(Conrad et al., 2004) and the discontinuation of feeding soy formula normalized the TSH 
concentration in three weeks (Jabbar et al., 1997). Even in healthy adults, daily consumption 
of soybeans (30 g/d) for 1 mo significantly increased TSH, although it was still within the 
normal range and no change in thyroid hormones were observed. Similarly, the cessation of 
soy consumption corrected the problem (Ishizuki et al., 1991).  
The underlying mechanism for the inhibition of soy on thyroid function is closely 
related to iodine status. In the absence of iodide, the soy isoflavones, genistein and daidzein 
can irreversibly bind to thyroid peroxidase (TPO) and inhibit TPO-catalyzed iodination and 
coupling, thereby impairing thyroid hormone (T3 and T4) synthesis.  In presence of adequate 
iodide, genistein and daidzein act as alternate substrates for TPO to produce mono-, di-, and 
triiodoisoflavones (Divi et al., 1997). In addition, soy consumption may contribute to iron 
deficiency, which may in turn contribute to hypothyroidism since two important enzymes 
(TPO and hepatic 5’-deiodinase) in thyroid hormone synthesis are iron dependent. Hepatic 
5’-deiodinase catalyzes the conversion of T4 to T3, the active thyroid hormone 
(Zimmermann, 2006).  
Soy consumption is becoming popular in the Western world, especially among 
vegetarians and young persons, due to increased health consciousness. Most studies have 
focused on health benefits related to soy protein, isoflavones and phytate, but research on 
negative effects of soy food consumption is limited. It is important to investigate the effect of 
soy food consumption on women of childbearing age, who are at risk of mineral deficiencies 
due to menstrual losses and poor dietary habits.
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ABSTRACT  
Many health benefits are attributed to soy food intake, but data on mineral balance are 
limited. Our main objective was to determine the effect of soy foods intake for 10-wk on iron 
or zinc status in women of childbearing age. We also tested the effect on bone and thyroid 
hormones. Women (18-28 y) non-smokers without chronic disease, anemia, pregnancy, 
and/or irregular menstrual cycles were randomly assigned to either a soy (n=31) or an animal 
food (n=32) group. Blood and urine samples and 3-d dietary records were collected prior to 
and after intervention. At baseline, iron and zinc status, biochemical markers of bone, and 
thyroid hormones were not different between two groups. After intervention, no significant 
changes were observed in hemoglobin, transferrin saturation, serum iron, ferritin, or 
transferrin receptor concentrations, as well as the transferrin receptor-ferritin index. 
                                                 
1Funded by Iowa Soybean Association and Soyfoods Council 
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Intervention significantly decreased plasma zinc (5 µg/dl in each group) but not serum 
alkaline phosphatase (soy vs. animal food group: 1.1 vs. 1.2 IU/L) concentrations. Soy intake 
slightly increased (1.5 U/L) bone-specific alkaline phosphatase concentration, with the 
change being significantly different from the animal food group (-0.7 U/L). No significant 
changes were observed in bone resorption marker, thyroid stimulating hormone or free 
thyroxine after soy food intake. In conclusion, incorporating 2 servings/day of soy foods with 
~20 g protein for 10-wk had no significant effect on iron and zinc status, bone resorption, or 
thyroid hormones and a beneficial effect on bone formation, compared to animal foods 
intake, in women of childbearing age.  
KEY WORDS Women of childbearing age, soy foods, iron, zinc, TSH  
INTRODUCTION  
Soy consumption has been grown popularity in the western world for its health 
benefits. Soy has been reported to beneficially modify blood lipids and lipoproteins (1-3), 
decrease cancer risk (4-6), attenuate bone loss (7-9), and help controlling diabetes (10, 11). 
Despite benefits, soy consumption may impair mineral balance in humans. Soy and its 
components contain about 1-3% phytic acid by weight (12), which binds to minerals such as 
zinc, iron, and calcium, thereby decreasing their bioavailability.  
Iron bioavailability has been shown to be extremely poor not only from soy foods 
(13) but also when soy was mixed other foods (13-15) in single meal feeding studies. For 
example, when full fat soy flour, textured soy flour, or isolated soy protein were substituted 
for egg albumin in a liquid diet, the absorption reduced from 5.5% to 1%, 1.9%, and 0.4%, 
respectively (13). In a mixed diet with beef and soy flour (1:1), iron absorption was 2-fold 
                                                                                                                                                       
2 None of the authors had a personal or financial conflict of interest. 
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lower than in a beef only diet (16). However, not all long-term feeding studies reported a 
negative effect on iron status. Daily consumption of 40 g soy protein isolate for 6 mo showed 
no adverse effect on iron status in perimenopausal women with normal or compromised iron 
status (17). On the contrary, the same amount of protein intake for 6-wk negatively affected 
iron status in postmenopausal women who had moderately elevated iron stores (18).  
Less data are available on the effect of soy foods on zinc absorption or balance. Soy 
protein-based diets are generally considered as having low zinc bioavailability due to the 
high phytate-to-zinc molar ratio (19). When the ratio exceeds 15 as is the case with soy 
products, zinc absorption is typically lower than 15% (19, 20). The inhibitory effect of 
phytate could be attenuated by dephytinization (21-23), or incorporating other protein 
sources, such as milk and meat to soy products (24, 25). Long-term feeding studies to assess 
the effect of soy on zinc balance are limited and conflicting. Daily consumption of a soy 
protein based diet for 3 mo was reported to cause a negative zinc balance and a reduction in 
plasma (25%) and neutrophil (31%) zinc concentrations in a small group (n=5) of human 
subjects (26), whereas no effect of soy on zinc absorption or balance was found in another 
long-term (82 days) feeding study (27).  
Influences of soy consumption on bone and thyroid status have also been reported. 
Soy isoflavones were shown to attenuate bone loss from lumbar spine in perimenopausal 
women (28), possibly by inhibiting bone resorption (29, 30). Soy-induced goiter was 
reported in infants fed with soy formula without iodine supplement (31-33), probably 
because soy isoflavones impair thyroid hormone synthesis in the absence of iodide (34). 
Additionally, soy consumption may cause iron deficiency, which may in turn contribute to 
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hypothyroidism since two important enzymes (thyroid peroxidase and hepatic 5’-deiodinase) 
in thyroid hormone synthesis are iron dependent (35).  
Overall, single meal studies clearly report an inhibitory effect of soy (mostly soy 
protein isolate) on iron and zinc absorption, but it is not clear whether consuming moderate 
amounts of soy foods daily will exert a significant impact on the iron and zinc status in 
healthy young adults. According to NHANES III in the United States, only 39% of female 
adolescents satisfied their recommended dietary allowance (Briefel et al., 2000). We 
therefore investigated the effect of incorporating commonly consumed soy foods daily for 10 
weeks on iron and zinc status in young female subjects. The potential effects of soy food 
intake on biochemical markers of bone and thyroid hormones were also assessed. 
SUBJECTS AND METHODS 
Subject Selection 
We recruited women aged 18-40 y by sending out emails and flyers throughout the 
Iowa State University. As shown in Figure 1, among the 195 subjects who responded, 87 
were initially screened by telephone and 74 were eligible to participate. Women with chronic 
disease, gastrointestinal problems, anemia, pregnancy, smoking, irregular menstrual cycles 
(<24 or >32 d menstrual cycle), extreme BMI (<18.5 or >30 kg/m2) or consumption of soy 
products more than two times per week were excluded. Women who met these criteria and 
were willing to be randomly assigned to either the soy (SF) or animal food (AF) group for 
10-wk were included. After pregnancy test and chemistry screen, 70 subjects were selected 
based on inclusion/exclusion criteria.  With 2 dropouts due to time conflict or consumption 
of mineral supplements and 5 lost to follow-up, we had a final sample size of 63 subjects.   
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Written informed consent was obtained from all subjects before baseline data 
collection. The study protocol, consent forms, and subject-related materials were approved 
by Iowa State University Human Subjects Review Committee (Institutional Review Board 
ID# 07-505).  
Study Design 
Once the subjects were selected based upon inclusion/exclusion criteria, they were 
randomly assigned to either the SF or AF group with foods (~two servings/d) provided by the 
study for 10 wk. Subjects came to the Human Metabolic Unit (HMU) on the Iowa State 
University campus three days per week (Monday, Wednesday and Friday) to eat their meals 
and to pick up the frozen meals to consume at home for the remaining days. Milk or yogurt 
was always consumed at home as a part of second meal every day. The weekly menu for 
subjects in each group is presented in Table 1; the soy protein content in SF group varied 
from 18 to 22 g per day, with an average of 19 g. In the meals we provided, total protein 
content and energy averaged 27 g and 2240 kJ per day for the AF group and 25 g and 2018 
kJ for the SF group, respectively. Since the majority of subjects were students, we provided 
soy protein bars to the SF group and whey protein bars to the AF group during the 7-day 
spring break. Subjects in the SF group were instructed not to consume any additional soy 
foods and limited to 1 serving/d of animal products, whereas the AF group was instructed not 
to consume more than 1 serving/d of animal foods (excluding dairy) in addition to the meals 
we provided during the study period. In addition, subjects were instructed not to take 
vitamin/mineral supplements. Instructions were provided for 24-hr urine collection.    
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Data Collection 
Questionnaires were administered to subjects at baseline to collect information on 
demographic characteristics, medical history, soy food intake history and reproductive 
history. Prior to and at the end of the intervention including the test meals, three-day dietary 
intake records were obtained; standing height, body weight, and waist and hip 
circumferences were measured by trained staff according to a standard protocol. Overnight 
fasting blood samples were drawn by phlebotomists and 24-hour urine samples were 
collected from each subject at baseline and the end of study.  Aliquots of serum/plasma and 
urine samples were stored at -80◦C until analysis.  
Laboratory Measurements 
Blood and urine samples were analyzed by a certified clinical laboratory (LabCorp, 
Kansas City, KS) for a general chemistry profile, complete blood count with differential, 
thyroid status (thyroid stimulating hormone and free thyroxine), iron status (serum iron, total 
iron binding capacity, transferrin saturation), and zinc status (plasma and urinary zinc, serum 
alkaline phosphatase). We measured serum ferritin using an immunoradiometric procedure 
and transferrin receptor concentrations using an enzyme immunoassay kit (TfR) following the 
manufacturer’s (Ramco Laboratories; Houston, TX) guidelines. Transferrin receptor-ferritin 
index (TfR-F index) was calculated as the ratio of serum transferrin receptor to log-transformed 
serum ferritin to determine non-anemic iron deficiency (36). Commercial ELISA kits were 
used to measure serum bone-specific alkaline phosphatase (BAP, bone formation marker) 
activity (Metra® BAP; Quidel Corporation; San Diego, CA) and serum cross-linked C-
terminal telopeptides of type-I-collagen (C-Tx, bone resorption marker) concentrations (serum 
CrossLaps® ELISA; Nordic Bioscience Diagnostics; Denmark) with an automated micro-titer 
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plate reader (ELx808U with KC Junior software V 1.14, BIO-TEK INSTRUMENTS®, Inc.; 
Winooski, VT) according to the manufacturer’s guidelines. Urinary isoflavones were 
determined using a modified HPLC procedure (37). The intra-assay and inter-assay CVs (%) 
were 5.3% and 6.0% for ferritin, 4.1% and 11.6% for transferrin receptor, 2.1% and 9.5% for 
BAP, and 1.8% and 7.3% for C-Tx, respectively.  
Statistical Analyses  
Statistical analyses were performed using SAS (version 9.1, Cary, NC) with results 
considered statistically significant at p≤0.05. The normality of data was checked before 
analysis with the Kolmogorov-Smirnov test and by examining the distribution of data using 
histograms. Descriptive statistics included mean (range) for age, height, weight, BMI, waist 
circumference, hip circumference, and waist-to-hip ratio; mean±SD for hemoglobin, serum 
iron, and serum alkaline phosphatase (ALP); and median (range) for serum ferritin, 
transferrin receptor, transferrin saturation, plasma and urinary zinc, and all dietary intakes. 
For normally distributed data, an unpaired student t-test was performed for between group 
comparisons and a paired student t-test was used for within group comparisons. For data that 
were not normally distributed, comparisons were conducted using a Mann-Whitney test 
between groups and a Wilcoxon signed-rank test within groups. Samples with serum ferritin 
values <1 µg/L (n=5 out of 126 measurements) were assigned to a value of 2 µg/L for 
statistical analysis.  
RESULTS 
Subject Characteristics 
A total of 63 subjects completed the 10-week dietary intervention. Table 2 shows the 
baseline characteristics of subjects by group. At baseline, subjects did not differ significantly 
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in age, height or hip circumference between the two groups. The significant difference in 
weight, BMI and waist circumference between two groups was because one subject in the AF 
group was within the obese range with weight >90 kg, BMI >30 kg/m2, and waist 
circumference>90 cm. The majority of the 63 subjects were Caucasian with 1 African 
American, 1 Hispanic/Latino, 11 Asian, and 2 with mixed race.  
Dietary Intakes   
Nutrient intakes were calculated from three-day dietary records using Nutritionist Pro 
(version 2.3.1, Stafford, TX). No significant differences between the groups were found in 
total dietary intake of energy, protein, carbohydrate, fat, iron, calcium, or vitamin C at 
baseline and the end of study (Table 3). However, the soy foods we provided to SF group 
contributed to the slightly higher intake of iron (5.2 mg vs 4.0 mg), calcium (395 mg 
compared to 319 mg), and vitamin C (6.2 mg vs 5.2 mg) than the AF group. However, total 
iron and calcium intake significantly increased in the AF group despite higher content of iron 
and calcium of soy foods. Dietary vitamin C intake decreased significantly in both groups 
post intervention (p<0.001).  
Most subjects met the current Dietary Reference Intake (DRI) (38) of protein (46 g/d) 
and carbohydrate (130 g/d) prior to and after the intervention. However, more than half of the 
subjects had a dietary intake of iron and calcium lower than the DRI values (18 mg/d iron 
and 1000 mg/d calcium) before and after the intervention (39, 40). In addition, the number of 
subjects who did not meet the current DRI for vitamin C (75 mg/d) increased from 12 to 22 
in the AF group and from 9 to 20 in the SF group.  
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Compliance  
Since subjects only consumed 3 out of 14 provided meals per week at our HMU, 
compliance for soy food intake was checked on six subjects randomly selected in each group 
by assessing urinary isoflavones at baseline and post intervention. There was no significant 
difference between the two groups at baseline (AF vs. SF: 2524 vs. 742 µg/24 hr urine). As 
expected, the SF group had a higher urinary isoflavone excretion than the AF group after 
intervention. Total urinary isoflavones significantly increased by 11-fold (from 742 to 8052 
µg/24 hr urine) in the SF group, whereas a 1.7-fold non-significant decrease (from 2524 to 
1486 µg/24 hr urine) was observed in the AF group, indicating excellent compliance.  
Effect on Iron Status  
Iron status before and after soy feeding is presented in Table 4. Average hemoglobin 
concentration was 13 g/dl for both groups and no change was observed after intervention. The 
median values for serum iron, ferritin, transferrrin receptor, and transferrin saturation were 
within the normal range at baseline and after intervention. Although serum iron declined in the 
SF group after intervention, the reduction was not significantly different from the AF group 
(-4.8 vs 3.2 µg/dl). Additionally, no changes were observed in transferrin saturation or 
transferrin receptor concentrations. Serum ferritin and transferrin receptor-ferritin index 
(TfR-F index) slightly decreased in both groups, but the changes were not significantly 
different between the SF and AF groups (serum ferritin: -1.2 vs -1.4 ng/ml; TfR-F index: -
0.13 vs -0.18). After intervention, the number of subjects who had iron deficiency (ID) based 
on serum ferritin <15 ng/ml (41) increased from 10 to 11 in the SF group and remained as 11 
in the AF group. If TfR >8.3 ng/ml was used to identify tissue iron deficit, the number 
declined from 7 to 3 in the SF group, and 9 to 3 in the AF group. If the TfR-F index >4.5 was 
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used to identify non-anemic ID (36), the number declined from 18 to 14 in the SF group and 
from 20 to 18 in the AF group. No treatment effect was found on serum ferritin after the 
adjustment of baseline ferritin in our study.  
Effect on Zinc Status 
Zinc status was assessed by measuring zinc concentration in the plasma and urine. 
The median plasma and urinary zinc concentrations were within the normal range for both 
groups prior to and at the end of intervention. As shown in Table 5, plasma zinc decreased 
significantly by 5 µg/dL in both groups. Although an increase (5 µg/g creatinine) in urinary 
zinc excretion occurred in the SF group, it was not significantly different either from baseline 
or compared with the change observed in the AF group (-18 µg/g creatinine). Moreover, 
serum ALP declined in the AF group and was significantly lower than in the SF group after 
intervention (p=0.017), but the ALP change did not differ between the SF (1.13 IU/L) and 
AF groups (-1.23 IU/L). 
Effect on Biochemical Markers of Bone and Thyroid Hormones 
Based upon the purported effect of soy isoflavones on bone, we assessed biochemical 
markers for bone formation (BAP) and resorption (C-Tx) (Figure 2). At 10-wk, BAP 
increased in SF group (1.5 U/L) but decreased in AF group (-0.7 U/L), and the change was 
significantly different (p=0.024) between two groups. We found no significant effect of 
treatment on C-Tx. To determine the effect of soy consumption on thyroid status, we tested 
thyroid stimulating hormone (TSH) concentration (Figure 3). After intervention, TSH 
declined by 13% in the AF group (p=0.018), whereas no significant change was observed in 
the SF group. The change in TSH (-0.39 vs 0.11 uIU/dL) was significantly different between 
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two groups. Further analysis of thyroxine (T4) found no significant difference between the 
two groups and no change from baseline to post intervention within each group. 
DISCUSSION 
Although a body of evidence exists on the inhibitory effect of soy foods on iron and 
zinc bioavailability from single meal studies, data are limited from long-term studies. This 
10-wk feeding study demonstrated that soy food intake had no detrimental effects on iron or 
zinc status in young women of childbearing age. At the end of the study, no significant 
changes were observed in macronutrient intake, reflecting that subjects adjusted their diets to 
maintain their habitual dietary intake and meals we provided did not contribute to additional 
nutrient intake. Iron intake was found to significantly increase only in the AF group, despite 
the higher iron content of the soy versus animal foods that we provided (5.2 versus 4.0 mg). 
It was likely that subjects in the AF group consumed fewer animal products before 
intervention and probably animal foods increased their iron intake. Similarly, the significant 
increase in calcium intake in the AF group may have been due to the increased dairy products 
intake during the study. Surprisingly, vitamin C intake declined in both groups, probably 
because of less consumption of vitamin C rich fruits and vegetables during the intervention. 
Since ascorbic acid may not markedly affect non-heme iron absorption from a complete diet 
(42), we do not expect that the reduction of dietary vitamin C had a significant effect on iron 
status.  
It is important to investigate the effect of soy consumption on iron and zinc status 
among women of childbearing age, who are at risk of iron deficiency due to substantial 
menstrual iron losses and poor dietary habits (43). Based on a cutoff value of 12 g/dl 
hemoglobin (41), none of the subjects were anemic either at baseline or at the end of 
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intervention. After 10 wk of intervention, serum iron decreased by 7% in the SF group, but 
no significant changes in iron indicators (hemoglobin, serum iron, transferrin receptor, 
transferrin saturation, and serum ferritin) were observed in the AF or SF groups, indicating 
that soy feeding did not impair iron status in our study. Although serum iron and transferring 
saturation are widely used in iron deficiency screening, their use is limited by the daily 
fluctuation of serum iron (CDC, 2008; Zimmermann, 2008). Recently, TfR-F index was 
suggested to be a useful indicator for subclinical iron deficiency in healthy subjects (44, 45). 
If TfR-F index was used to classify subjects with non-anemic ID (36), the proportion of iron 
deficient subjects decreased by 6.5% and 12.5%, respectively, in the AF and SF group, 
showing an improvement in iron status with intervention. This is consistent with the findings 
from several but not all studies. A large scale cross-sectional study (1308 men and 1541 
women aged over 20 y) in China (46) found the difference in mean serum ferritin 
concentration across quartiles of tofu intake was not significantly different. In addition, our 
previous study also demonstrated that the consumption of 40 g soy protein isolate daily for 
24 wk did not have significant effect on iron status in perimenopausal women, though 
treatment reduced serum iron by 11% and transferrin saturation by 3-7% (n=69) (17). 
Overall, we did not find negative effect of soy food intake on iron indices.  
However, these results contradicted our another study with postmenopausal women 
(n=15) with 6-wk soy protein isolate intake (40 g/d) showing a significant decrease in 
transferrin saturation (28%) and serum ferritin (30%) as well as a moderate reduction in 
serum iron (7%) (18). The disparity may be attributed to the different iron status of subjects 
at baseline (average serum ferritin concentrations of perimenopausal women compared to 
postmenopausal women: 15.5 vs. 65.4 ng/ml), in addition to the amount of soy protein intake 
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and the duration of intervention, because iron absorption in subjects with low iron stores may 
be higher than those with high iron stores (47). In our study, iron status of subjects with low 
iron stores were improved compared to those with high iron stores at the end of study. The 
fact that postmenopausal women generally have high iron stores compared to premenopausal 
women, as reflected by serum ferritin concentrations (48) may be one of the reasons why a 
significant reduction in iron status was observed in postmenopausal women but not in 
premenopausal or perimenpausal women with soy consumption.  
Zinc deficiency is not common in North America due to good dietary habits (40). In 
the present study, no subjects were zinc deficient (based on criteria of plasma zinc <70 µg/dl 
and urinary zinc <100 µg/g creatinine (49)) at baseline and only two subjects developed zinc 
deficiency in the AF group after intervention. A long-term crossover study reported that 
lactoovovegetarian diets for 8 wk in women (n=22) reduced zinc absorption by 35% and 
plasma zinc concentration by 5% (50). Our study confirmed these results by showing an 8% 
reduction in plasma zinc concentration (p=0.04), with the values being normal after soy 
feeding. Plasma zinc is a relatively insensitive indicator for zinc status, although is widely 
used as screening test. Plasma zinc concentration is generally stable but decreases after 
several weeks of severe dietary restriction when tissue zinc is reduced. Thus, it poorly 
reflects tissue zinc status and cannot be used to identify marginal zinc deficiency (51). In our 
study, the reduction in plasma zinc may not have physiological significance, although it was 
statistically significant. We did not observe a compensatory reduction in urinary zinc 
excretion or decreased activity in serum ALP, despite a decline in plasma zinc concentration. 
Another feeding study observed a more marked reduction in plasma zinc concentration after 
daily consumption of a soy protein based diet for 3 mo in human subjects (n=5), causing a 
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negative zinc balance and a 25% reduction in plasma zinc concentration (26). The lower 
intake of soy protein per day (19 vs. 69 g) and the shorter study duration (10 vs. 12 wk) may 
have contributed to the moderate influence of soy on zinc status in our study compared to the 
previous study. Dietary zinc intake may also affect zinc status; however, we could not assess 
the dietary zinc intake in our subjects because the dietary analysis software does not provide 
this information. Additionally, our subjects were premenopausal women with lower plasma 
zinc than male subjects used in the previous study; whether sex and baseline zinc status 
influence the effect of soy consumption on zinc status has not been investigated thoroughly. 
On the other hand, we were surprised to find a 9% reduction (p=0.048) in plasma zinc in the 
AF group with animal foods intake, considering that meat is a good source of zinc. Although 
dietary zinc data were not available, a slight decrease in urinary zinc concentration paralleled 
with a slight reduction in the activity of serum ALP (a zinc dependent enzyme) in the AF 
group after intervention, suggesting that dietary zinc intake might be slightly reduced after 
feeding, because previous study reported that urinary zinc declined proportionately to the 
reduction of dietary zinc intake (52). If endogenous fecal zinc excretion and dietary zinc 
intake were assessed, together with other zinc indicators, we would have been able to better 
evaluate zinc status in these subjects. 
Some (53, 54), but not all (55, 56), human studies reported that the consumption of 
soy isoflavones increased bone formation and decreased bone resorption. We did not find 
significant changes in bone formation or resorption after intervention, indicating that our 
intervention with soy foods might not have been long enough to exert a significant effect on 
bone. However, we were surprised to find that serum BAP increased with soy foods intake 
but declined with animal foods intake. The significant difference in BAP changes between 
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two groups may be due to the different types of protein they consumed during intervention. 
In addition, no evidence of soy affecting TSH and T4 was found in our study. This was 
consistent with the results of a recent study, showing no significant effects on serum thyroid 
hormones after 57 d of soy protein isolate intake in young men (n=35) (57). Surprisingly, 
TSH significantly declined in the AF group after intervention, indicating an improvement in 
thyroid hormone status. We speculated that this was due to the increased consumption of 
dairy products, which are a good source of dietary iodine in the United States (58). 
In conclusion, we found no detrimental effect on iron status and a marginal effect on 
zinc status after consuming moderate amount of soy foods that are currently available in the 
market to women of childbearing age. We observed an improvement in bone formation after 
soy food intake compared to animal food consumption. However, no significant effects on 
thyroid hormones or bone resorption were observed with soy consumption in this study.  
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Table 1 
Weekly menu for subjects in animal and soy food groups1 
  AF                            SF  
Monday    chili without beans    soy chili 
             crackers/peanut butter    crackers/soynut butter 
             yogurt      soy yogurt 
Tuesday     meat balls      soy meat balls 
             pasta with sauce    pasta with sauce 
             milk      soy milk 
Wednesday taco with beef     taco with soy  
             yogurt      soy yogurt 
Thursday    beef                   tofu 
             rice      rice 
              stir fried peas and carrots   stir fried peas and carrots 
              milk      soy milk 
Friday        burger/bun     soy burger/bun 
              milk      soy milk 
Saturday green peas     edamame 
              rice      rice 
              carrots      carrots 
              peanuts     soy nuts 
              yogurt      soy yogurt 
Sunday      chicken     soy chicken 
             pasta/sauce     soy pasta/sauce 
             milk      soy milk 
1AF= animal foods; SF= soy foods; milk and yogurt were consumed as second serving and 
always consumed at home; condiments were provided with each meal to subjects when they 
consumed at site. 
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Table 2   
Baseline characteristics of the subjects by group1 
 Treatment Group 
AF (n=31) SF (n=32) 
Age (y) 21 [18-27] 22 [18-28] 
Height (m) 1.66 [1.54-1.76] 1.65 [1.54-1.77] 
Weight (kg)* 64.0 [51.1-96.2] 60.0 [49.0-76.8] 
BMI (kg/m2)* 23.3 [18.5-33.9] 22.0 [18.5-27.2] 
Waist Circumference (cm)* 72.6 [61.2-98.6] 69.6 [58.7-78.2] 
Hip Circumference (cm) 100.3 [89.4-123.2] 97.5 [86.4-107.7] 
Waist-to-Hip Ratio 0.72 [0.63-0.83] 0.71 [0.65-0.77] 
1Mean [min-max]; AF= animal foods; SF= soy foods; student’s t-test was used to compare 
the differences between groups for height, BMI and waist to hip ratio; Mann-Whitney test 
was performed for comparison of age, weight, waist circumference and hip circumference 
between groups; *p<0.05. 
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Table 3  
Daily dietary intake of subjects at baseline and the end of study1 
 Treatment Group 
 AF (n=31) SF (n=32) 
 Energy (kJ) 
baseline 6665 [3483-10320] 6958 [4023-10802] 
post 6866 [4421-13083] 7034 [4375-9965] 
Protein (g) 
baseline 66 [42-97] 67 [39-109] 
post 69 [42-189] 68 [42-97] 
Carbohydrate (g) 
baseline 233 [82-321] 226 [158-414] 
post 231 [134-330] 222 [116-391] 
Total Fat (g) 
baseline 51 [24-112] 53 [17-100] 
post 57 [31-122] 57 [24-99] 
Iron (mg) 
baseline 13.7 [6.8-36.5] 14.0 [7.7-32.8] 
post 14.4 [7.4-31.3]a 14.2 [8.5-31.9] 
Calcium (mg) 
baseline 725.6 [285.8-1803] 827.5 [312.2-1580] 
post 854.5 [446.5-1942]b 931.2 [466.6-1330] 
Vitamin C (mg) 
baseline 98.1 [21.4-434.2] 97.0 [10.9-322.1] 
post 51.2 [18.0-129.9]c 54.6 [14.5-229.0]c 
1Median [min-max]; AF= animal foods; SF= soy foods; non-parametric tests were used to 
compare the difference within the group or between groups; letters represent differences 
between baseline and the end of study within each group; ap<0.05, bp<0.01, cp<0.001; no 
significant difference was found in any dietary factors between groups at baseline and then 
end of study; the change of any dietary factor did not differ between two groups. 
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Table 4  
Iron status of subjects at baseline and the end of study1 
Treatment Group Normal Range 
          AF (n=31) SF (n=32) 
Hemoglobin (g/dl)2 11.5 - 15 
baseline 13.19 ± 0.76 13.28 ± 0.58 
post 13.39 ± 0.62 13.45 ± 0.58 
change  0.02 ± 2.77 -0.53 ± 2.60 
Serum Iron (μg/dl)2 35 - 155 
baseline 99.3 ± 39.7 94.8 ± 51.4 
post 102.5 ± 34.3 90 ± 43.7 
change 3.2 ± 44.2 -4.8 ± 65.4 
Transferrin Saturation (%) 15 - 55 
baseline 27 [10-53] 23 [10-82] 
post 28 [13-48] 24 [10-54] 
change 3 [-24-23] 2 [-52-41] 
Transferrin Receptor (μg/ml) 2.9 - 8.3 
baseline 6.39 [2.82-10.84] 6.16 [4.27-10.86] 
post 6.18 [3.41-14.81] 6.19 [3.71-14.20] 
change -0.11 [-4.37-4.85] -0.16 [-2.77-3.62] 
TfR-Fer Index <4.5 
baseline 5.15 [1.84-22.82] 4.86 [2.68-26.65] 
post 4.94 [2.19-20.33] 4.47 [2.92-45.81] 
change -0.18 [-17.10-12.55] -0.13 [-4.17-19.16]
Serum Ferritin (ng/ml) 12 - 150 
baseline 21.2 [2.0-110.8] 23.6 [2.4-77.8] 
post 18.8 [2.0-91.1] 22.5 [2.0-65.7] 
change -1.4 [-35.2-26.8] -1.2 [-46.7-27.4] 
1Median [min-max]; 2Mean±SD; AF= animal foods; SF= soy foods; student’s t-test was used 
for comparison of hemoglobin and non-parametric tests were utilized for comparison of iron 
indices; no significant difference was found between two groups for any parameter at 
baseline and the end of study; no significant changes were observed in any parameter at the 
end of study.  
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Table 5   
Zinc status of subjects at baseline and the end of study1 
Treatment Group Normal Range 
AF (n=31) SF (n=32) 
Plasma Zinc (μg/dl)  70 - 100 
baseline 80.0 [60-142] 83.0 [62-146]  
post 73.0 [52-115] 76.5 [53-129]   
change -5 [-49-46]a -5 [-73-38]a  
Urine Zinc (μg/g Creatinine)  100 - 900 
baseline 265 [50-838] 279 [50-698]  
post 259 [37-860] 314 [114-911]  
change -18 [-579-487] 5 [-469-411]  
Serum Alkaline Phosphatase (IU/L)2  25 - 150 
baseline 55.19 ± 10.8 59.78 ± 10.86  
post* 53.97 ± 11.89 61.09 ± 11.17  
change -1.23 ± 7.24 1.13 ± 5.63  
1Median [min-max]; 2Mean±SD; AF= animal foods; SF= soy foods; student’s t-test was used 
for comparison of serum alkaline phosphatase, and non-parametric tests were utilized for 
comparison of serum and urinary zinc; letters represent differences between baseline and the 
end of study within each group; ap<0.05; symbols represent differences between groups; 
*p<0.02.  
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Figure 1  
Subject recruitment1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1AF= animal foods; SF= soy foods. 
Excluded     n=14 
• Extreme BMI (6) 
• Work schedule conflict (6) 
• Irregular menstruation (1) 
• Consumption of soy foods 
>2 times/wk (1) 
Subjects Responded  
n=195 
Assessed for Eligibility via Telephone Screening 
n=87
Completed Blood Screen and Pregnancy Test: 
Randomized to Treatment 
n=70 
SF Group 
n=37
Completed Pre-Baseline Screening: 
Initial Eligibility Confirmed 
n=73 
AF Group 
n=33
Excluded     n=3 
• Chronic disease (3) 
Completed Treatment 
n=32
Completed Treatment 
n=31
Lost to Follow-up   n=3 
Dropped Out           n=2 
• Wanted to take iron 
supplement (1) 
• Time conflict (1) 
Lost to Follow-up   n=2
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Figure 2 
Effect of soy food consumption on biochemical markers of bone1 
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1 Animal foods; Soy foods; Median+Interquartile range; bone formation and 
resorption prior to and at the end of study were reflected by BAP and C-Tx respectively; non-
parametric tests were performed for comparison; n=31 for animal food group and n=32 for 
soy food group; *p<0.05.  
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Figure 3  
Effect of soy food consumption on thyroid-stimulating hormone1 
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1 Animal foods; Soy foods; Mean±SEM; Student’s t-test was used to examine the 
difference within group and between groups; n=31 for animal food group and n=32 for soy 
food group; *p<0.05, #p<0.02. 
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